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Abstract
Three diamidines (DB 75, DB 867 and DB 1192) were selected and their ability to cure T. evansi experimentally infected goats
was investigated. A toxicity assessment and pharmacokinetic analysis of these compounds were additionally carried out.
Goats demonstrated no signs of acute toxicity, when treated with four doses of 1 mg/kg/day (total dose 4 mg/kg).
Complete curative efficacy of experimentally infected goats was seen in the positive control group treated with diminazene
at 5 mg/kg and in the DB 75 and DB 867 groups treated at 2.5 mg/kg. Drug treatment was administered once every second
day for a total of seven days. Complete cure was also seen in the group of goats treated with DB 75 at 1.25 mg/kg. DB 1192
was incapable of curing goats at either four-times 2.5 mg/kg or 1.25 mg/kg. Pharmacokinetic analysis clearly demonstrated
that the treatment failures of DB 1192 were due to sub-therapeutic compound levels in goat plasma, whilst compound
levels for DB 75 and DB 867 remained well within the therapeutic window. In conclusion, two diamidine compounds (DB 75
and DB 867) presented comparable efficacy at lower doses than the standard drug diminazene and could be considered as
potential clinical candidates against T. evansi infection.
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Introduction
Aromatic diamidines bind to the minor groove of DNA and
display a broad spectrum of antitrypanosomal activity [1,2]. They
exert their biological activity by primarily binding at A-T rich sites
of DNA and then inhibiting one or more of the DNA dependent
enzymes (such as topoisomerases or nucleases) or by directly
impeding the transcription process. The selective binding to
kinetoplastic DNA has also been suggested to play a vital role in
the action of aromatic diamidines against pathogens [1]. Several
novel diamidine analogues were found to be highly effective
against Trypanosoma evansi [3], the causative agent of Surra, which
presents itself as a fatal wasting disease in many domestic and wild
animals, inhabiting South America, Africa and Asia [4–6].
Through mechanical transmission performed by biting flies
(Tabanids), infection can quickly spread amongst close-living
herds of cattle, water buffalo, horses and camels [7]. With the
hindrance of resistant strains, unavailable and toxic drugs and the
great economic losses involved, controlling this disease is a
complex process [8], which could be simplified if alternative
chemotherapeutic agents were obtainable. Since chemotherapy is
the main form of control for Surra, existing drugs need to be
replaced with improved compounds providing a more economical,
effective and safer alternative against T. evansi [9].
T. evansi is considered endemic in certain areas of the Canary
Islands, especially southern Gran Canaria. This was originally due
to the importation of a male dromedary camel in 1997, from the
neighbouring area of West Africa, where Surra is highly prevalent.
Camels were primarily imported for labour purposes, but are
nowadays principally raised for the tourism industry [10].
Seroprevalences in camels on the Canary Islands have been
calculated to be around 4.8% to 9%, between 1997 and 1999 [11].
Although camels and horses are the major hosts affected on these
islands, dissemination of the disease in other hosts has not yet been
ruled out. Above all, goats appear to play an important role in
disease epidemiology, especially as potential reservoir hosts [12. 13].
Three lead compounds (DB 75, DB 867 and DB 1192) were
previously selected based on their in vitro activity and in vivo efficacy
within a mouse model, their reduced potential for drug resistance,
low cytotoxicity against mammalian cells and no toxicity in mice
[3,14]. Additionally, these compounds were selected due to their
estimated cost-effective manufacture as possible clinical candidates
against T. evansi.
Toxicity studies with these compounds have not yet been
performed. Hence an experiment was conducted to determine
whether the selected compounds produce signs of acute toxicity in
goats, when administered at cumulative multiple doses of 1 mg/
kg. Should these compounds exert no toxic effects at the tested
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20836compound dose, it may be possible to formulate a safe and
successful treatment schedule to determine the efficacy of these
diamidines against T. evansi infected goats.
The objectives of this study were the establishment of
experimental infection of a local T. evansi strain in goats and the
examination of chemotherapeutic effects of three selected lead
compounds by comparing with diminazene aceturate (standard
drug for T. evansi infection) in experimentally infected goats.
Additionally, pharmacokinetic parameters were also examined for
understanding the levels of drug that might be associated with
efficacy and/or toxicity.
Materials and Methods
Ethics statement
The experimental protocol used was approved by the ethics
committee for animal experimentation by the Veterinary Faculty
of the University of Las Palmas on June 21, 2006 with the
reference number 14/2006. This study was conducted under the
strict guidelines set out by the FELASA for the correct
implementation of animal care and experimentation.
Trypanosome strain
The Canaries (Rubio) strain of T. evansi was used for goat
infection in the efficacy and pharmacokinetic studies. This strain
was originally isolated by K Gillingwater in 2006, from a 22 years
old dromedary camel on Gran Canaria, Spain. The camel blood
was immediately inoculated into mice and after a single mouse
passage, used for experimental infection of the goats.
Mice
Female NMRI mice weighing between 25 – 30 g were used for
strain isolation. All mice were specific pathogen free (SPF) and
were maintained in standard Macrolon type II cages, at 22uC and
with a relative humidity of 60 – 70%. Water and pelleted food was
provided ad libitum. All in vivo experiments performed complied
with the regulations set out by the Swiss Federal Veterinary Office.
Goats
The toxicity, efficacy and pharmacokinetic studies all took place
within the Veterinary Hospital of the University of Las Palmas in
Arucas, Gran Canaria, between June 2006 and January 2007. In
total, 33 female Canarian goats, weighing between 20 – 52 kg and
no less than six months old were purchased from a local dairy
farmer. The goats were placed inside open pens and allowed to
acclimatise for a week. Thereafter, the goats were given numbered
ear tags, weighed and checked for T. evansi infection using the
diagnostic methods described within this study. Any goats showing
positive results for previous T. evansi infection were removed from
the project (in this case, two goats were removed). The remaining
goats were then randomly divided into test groups, given
oxytetracycline against nasal exudate and ivermectin as a standard
anti-helminthic, before being placed into fly-proof pens. Through-
out the study period, the goats were given food (pelleted nutrients,
dried corn and hay), three times a day and water was provided
ad libitum.
Test compounds and stock solutions
Diminazene aceturate (D-7770, Sigma, St Louis, MO, USA),
was used as the standard positive control drug. The selected lead
diamidine compounds were previously synthesised in the labora-
tory of Professor David Boykin. The compounds DB 75, DB 867
and DB 1192 were used as the test compounds in these goat
studies based on their previous in vitro and in vivo activity and safety
profile [3,14].
The 10 mg/ml stock solutions of DB 75, DB 867 and DB 1192
were prepared in 10% DMSO on the day of the first
administration and were stored at 4uC. For the control compound,
a 50 mg/ml stock solution of diminazene aceturate was also
prepared in 10% DMSO.
Toxicity trials
For the toxicity trials, six goats were divided into three groups of
two. Each group was allocated to one selected diamidine
compound. Both goats in each group undertook four compound
applications of 1 mg/kg, given at two hour intervals, over a total
six hour period as intramuscular injection into the lower third
region of the neck muscles. The goats were individually observed
and assessed for signs of acute toxicity.
Diagnostic tests
Various diagnostic tests were used to evaluate the curative
efficacy of the compounds, over a five month follow up period.
The haematocrit centrifugation technique [15], was utilised as the
standard parasitological test. The serological CATT/T. evansi test
was performed to determine the presence or absence of antibodies
[16]. As a validating molecular based technique, a mini-exon 18S
ribosomal PCR method designed for the detection of parasite
DNA was also applied [17].
Experimental infection and treatment
Fresh camel blood (400 ml) was collected from the jugular vein
of a camel and 200 ml volumes inoculated (i.p.) into two mice.
Once a parasitaemia had established, blood was collected via
cardiac puncture and mixed with phosphate buffered saline with
glucose (PSG) to provide the T. evansi suspension used for
experimental goat infection. Thereafter, all 25 goats were
experimentally infected intravenously (i.v.), with 10
6 parasites/
goat.
Goats were divided into 8 groups, where group 1 contained four
goats whilst group’s 2 to 8 each contained three goats. After
confirmation of infection, treatment was applied to the various
groups of goats as follows: untreated control, given no compound
treatment (Group 1); positive control, given 5 mg/kg diminazene
aceturate (Group 2); given 2.5 mg/kg and 1.25 mg/kg of DB 75
(Group 3 and 6), of DB 867 (Group 4 and 7) and of DB 1192
(Group 5 and 8), respectively. All test compounds were
administered intra-muscularly with four applications, on days 32,
34, 36 and 38 post-infection. Thereafter, follow up diagnostic
methods were carried out for five months post treatment.
Measurement of drug levels and pharmacokinetic
parameters
Blood samples (4 ml volumes) were taken for pharmacokinetic
analysis at the following time points of 0.50, 1, 2, 4, 8, 24, 48, 96
and 192 hours after the administration of the fourth compound
injection, using sterile VacutainerH (Becton Dickinson, Plymouth,
UK) tubes, containing the anticoagulant, ethylene diamine tetra
acetic acid (EDTA). In addition, blood samples were taken shortly
before each compound injection was applied, to determine the
trough levels. All samples were centrifuged at 3000 g for ten
minutes. Subsequently, the plasma was removed, placed into
sterile polypropylene cryotubes and stored away from light at
280uC.
Mass spectrometry analysis was performed on all plasma
samples using 25 ml aliquots. Calibrators were prepared separately
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and DB1192 were prepared in water. Curves were then prepared
and analysed in duplicate, at both the beginning and the end of the
analytical run. Concentrations of diminazene, DB 75, DB 867 and
DB 1192 were determined by Liquid Chromatography/Triple
Quadrupole Mass Spectrometry (HPLC/MS-MS). The pharma-
cokinetic parameters were determined using MicrosoftH Excel
software, with a functional set of add-ins applied, together with a
graphical programme (GraphPad Prism 5, GraphPad Software
Inc, USA).
Results
Establishment of experimental infection in goats
Successful establishment of a T. evansi goat model of infection
was achieved through infection with a local T. evansi strain,
originally isolated from a camel. The parasitaemia observed in the
infected camel was sporadic and not always detectable. Therefore,
several mice were inoculated with blood from the camel to enable
propagation of a sufficient number of trypanosomes, allowing each
goat to be initially inoculated with 10
6 parasites. Inoculation
number was determined using a haemocytometer.
Toxicity of test compounds
The signs of acute toxicity seen in the goats for DB 75, DB 867
and DB 1192 are shown in Table 1. Signs of acute toxicity
assessed, included tremors, lacrimation, excess salivation, irritation
(scratching at injection site or general discomfort), excess
urination, diarrhoea, hypertension and hypotension. For goats
treated with DB 75 and DB 867, some irritation was observed by
means of scratching at the injection site. These goats additionally
showed a short phase of discomfort, immediately after each
compound was applied. These symptoms disappeared after ten
minutes and the goats returned to their normal behaviour.
Efficacy of test compounds against infection
The results obtained from the efficacy study by three diagnostic
tests, the haematocrit centrifugation technique (HCT), the card
agglutination test (CATT/T. evansi) and the polymerase chain
reaction (PCR), are shown in Table 2, 3 and 4, respectively.
Infection was confirmed positive in all goats before treatment
commenced. The control group (group 1), which received no drug
treatment, remained positive for the HCT, strongly positive (+++)
for the CATT/T. evansi and positive for the PCR method during
the complete five month follow up period. Two of the four control
goats died on days 114 and 156 post infection. The positive control
group (group 2), treated with 5 mg/kg diminazene aceturate,
demonstrated negative results for both the HCT and the PCR
methods for the whole duration of the study. The CATT/T. evansi
serological test demonstrated a gradual decrease from strongly
positive (+++) to negative (2) for 2 out of the 3 goats.
Goats treated with DB 75 at either 2.5 mg/kg or 1.25 mg/kg
(groups 3 and 6, respectively) demonstrated negative results for
both the HCT and PCR methods for the complete five month
follow up. For the 2.5 mg/kg group (group 3), goats showed a
strong positive reaction (+++) towards the CATT/T. evansi test
until day 35 post treatment, when a gradual decrease occurred
leaving one goat negative and two goats weakly positive (+). A
gradual decrease in antibody reaction was also seen for the
1.25 mg/kg group (group 6) with two goats completely negative
and one showing an intermediate result (++) at the end of the
follow up period. A similar pattern was seen in goats treated with
DB 867 at 2.5 mg/kg (group 4), where all three animals remained
negative for the HCT and the PCR methods during all five
months. The same situation was recorded for the goats treated
with DB 867 at 1.25 mg/kg (group 7) for the HCT and PCR
methods, until day 126 post treatment, when the PCR became
positive for two out of three goats. By day 140 post treatment, all
three goats had relapsed and tested positive with PCR. On day
150 post treatment, trypanosomes were visibly observed in all
three goats. The serological results for DB 867 treated goats
showed a good correlation with the other two diagnostic tests used.
At 2.5 mg/kg treatment dose (group 4), the CATT/T. evansi
results gradually decreased throughout the trial, with two negative
goats and one weakly positive (+) goat at the end. In contrast, the
1.25 mg/kg treated group (group 7) demonstrated a gradual
decrease in CATT/T. evansi results by day 84 post treatment.
Thereafter, an increase in reaction intensity was seen from day 140
post treatment onwards, as all three goats relapsed.
For DB 1192 treated goats given the 2.5 mg/kg dose (group 5),
the HCT remained negative for just under 2 weeks before
trypanosomes reappeared in two of the three goats. These two
goats were then removed from the study. The third goat remained
HCT negative, but later died on day 35 post treatment. The PCR
method detected positive reactions in all three goats on days 7, 14
and 21 post treatment, respectively. The CATT/T. evansi reaction
remained strongly positive (+++) for all three goats. For the
1.25 mg/kg treated goats (group 8), one goat became HCT
Table 1. Signs of acute toxicity investigated after the i.m. application of DB 75, DB 867 and DB 1192 in a multiple compound
application (461 mg/kg) toxicity trial.
Group
Lead
compound
Toxicity
trial
Goat
number Signs of acute toxicity*
Hypo Hyper (L) (S) (Tr) (Ir) (U) (D)
1 DB 75 multiple 0823 x x x x x 3 xx
0865 x x x x x 3 xx
2 DB 867 multiple 0866 x x x x x 3 xx
0850 x x x x x 3 xx
3 DB 1192 multiple 0818 x x x x x x x x
0810 x x x x x x x x
The presence or absence of each sign is depicted as a (3) or as a (x), respectively.
*Signs of acute toxicity: Hypo: Hypotension; Hyper: Hypertension; (L): Lacrimation; (S): Salivation (excess); (Tr): Tremors; (Ir): Irritation;( U ) :Urination (excess); (D):
Diarrhoea.
doi:10.1371/journal.pone.0020836.t001
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treatment, all three goats demonstrated trypanosomes in the blood
and hence were removed from the study.
Concentration of test compounds in blood
The compound plasma levels can be seen in Figure 1 for a) the
standard drug, diminazene, b) DB 1192, c) DB 75 and d) DB 867.
The plasma samples taken were analysed by HPLC/MS-MS to
determine the drug concentrations (in ng/ml). From these values,
the averages from the experimental goats in each group were
calculated and drug concentration versus time curves were plotted
with a line of best fit applied, corresponding to either the high or
low compound dose tested.
For the standard control drug (diminazene), the in vitro IC50 value
obtained for 72 hours is 12.5 ng/ml, with an estimated MIC of
50 ng/ml [14]. At 72 hours after the end of treatment, the
concentration of diminazene in goat plasma was 1112 ng/ml, which
is a 22-fold greater concentration than the 50 ng/ml MIC value.
Even after 192 hours, the diminazene concentration in goat plasma
was 568 ng/ml,which still remains wellwithin the therapeuticrange.
Through previous in vitro testing of DB 1192 against T. evansi,a n
IC50 value of 10.5 ng/ml was obtained for a 72 hour assay. The
minimal inhibitory concentration (MIC) of such a compound was
estimated at least four times greater than the IC50, so for DB 1192,
the estimated MIC would be around 40 ng/ml [14]. To establish
curative efficacy of an infected animal, the level of the compound in
plasma must exceed the MIC for a certain time period. If the
compound level in plasma falls below the MIC threshold too
quickly, the compound provides only sub-therapeutic concentra-
tions, which in turn will be insufficient to remove the parasites. At
72 hours, the compound concentration in the plasma was only
32 ng/ml. This value is already below the MIC threshold to ensure
successful therapeutic activity of DB 1192. At 192 hours after the
final compound injection was applied to goats treated with 2.5 mg/
kg, the compound concentration in plasma was only 10 ng/ml.
Thus, there is clear evidence why DB 1192 could not cure at
2.5 mg/kg goats experimentally infected with T. evansi. Further-
more, this relates to the lower dose of DB 1192 tested (1.25 mg/kg),
where compound concentrations in goat plasma at 72 hours were
only 18 ng/ml as compared to 40 ng/ml value for the MIC.
A similar pattern was seen for DB 75 at 2.5 mg/kg and
1.25 mg/kg as that of the standard drug, where the plasma
concentrations measured at 72 hours were 1923 ng/ml and
2223 ng/ml, respectively. DB 75 has an IC50 of 2.3 ng/ml at
Table 2. A five month follow up of an efficacy study for a T. evansi experimentally infected goat model, using the haematocrit
centrifugation technique (HCT), after treatment with Diminazene, DB 75, DB 867 or DB 1192 at various compound doses.
Group
Compound
Treatment
Goat
No. Follow up goat efficacy using haematocrit centrifugation technique (HCT) post treatment (in days)
27 171 42 1 2 83 54 24 95 67 08 49 81 1 21 2 61 4 01 5 0
1 Control 2255 ++ + ++ +++++++++ + + +
7397 ++ + ++ +++++++++ D
7374 ++ + ++ +++++++++ + + +
7314 ++ + ++ ++++++D
2 Diminazene 1773 + 2 2 22 222222222 2 2 2
5 mg/kg 7396 + 2 2 22 222222222 2 2 2
7388 + 2 2 22 222222222 2 2 2
3D B 7 5 7 3 9 0 + 2 2 22 222222222 2 2 2
2.5 mg/kg 7324 + 2 2 22 222222222 2 2 2
5406 + 2 2 22 222222222 2 2 2
4 DB 867 7319 + 2 2 22 222222222 2 2 2
2.5 mg/kg 5674 + 2 2 22 222222222 2 2 2
7386 + 2 2 22 222222222 2 2 2
5 DB 1192 7379 + 22+ Rem
2.5 mg/kg 7387 + 22+ Rem
7361 + 222 2 2 D
6D B 7 5 5 6 2 2 + 2 2 22 222222222 2 2 2
1.25 mg/kg 7366 + 2 2 22 222222222 2 2 2
7369 + 2 2 22 222222222 2 2 2
7 DB 867 7372 + 2 2 22 222222222 2 2 +
1.25 mg/kg 7341 + 2 2 22 222222222 2 2 +
7339 + 2 2 22 222222222 2 2 +
8 DB 1192 7384 + 22+ Rem
1.25 mg/kg 7383 + 2 ++ Rem
7360 + 22+ Rem
The results are depicted as negative (2) or positive (+) for motile trypanosomes observed in goat blood samples, along with goats, which died (D) or were removed
from the project (Rem) during the study period.
doi:10.1371/journal.pone.0020836.t002
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the plasma concentrations of DB 75 for both doses were above
1500 ng/ml and well within the therapeutic range and thus
explaining effective cure. Treatment with even lower doses than
1.25 mg/kg are still likely to be curative.
In the case of DB 867, the in vitro IC50 at 72 hours was
previously determined as 1.7 ng/ml and the MIC as 6.8 ng/ml
[14]. Both the 2.5 mg/kg and 1.25 mg/kg DB 867 treated goat’s
demonstrated compound concentrations in plasma at 72 hours
above 1850 ng/ml. After 192 hours, the compound concentration
levels were still within the therapeutic range. Goats treated with
the higher dose (2.5 mg/kg) of DB 867 were cured, whereas goats
treated with the lower dose of 1.25 mg/kg were seen to relapse
after 4.5 months post treatment.
Pharmacokinetic parameters
The maximum drug concentration (Cmax) obtained for the
control drug diminazene was $8637 ng/ml. In comparison, DB
75 and DB 867 produced Cmax values of $2530/$3115 ng/ml
and $3310/$3663 ng/ml for the 2.5/1.25 mg/kg treatment
doses tested, respectively (Table 5). At these Cmax values,
compound levels remained well over the therapeutic threshold
and no significant correlation was seen between the two doses
applied. DB 1192 demonstrated low Cmax values at both doses and
fell below the therapeutic threshold within the first 24 hours post
treatment. In addition, the DB 1192 Cmax value of $1563 ng/ml
at 2.5 mg/kg was approximately double that of the Cmax value of
$836 ng/ml at the lower dose of 1.25 mg/kg. The half lives (T
K) of DB 75 and DB 867 were found to be incredibly long as
compared to that of diminazene. As expected, DB 1192 had a
short half life at the ineffective doses tested in this study.
Discussion
In the present study, a constant detectable parasitaemia could
be achieved (which is prerequisite for efficacy trials) by using a less
virulent parasite strain (endemic in the Canary Islands) at a higher
inoculation dose (10
6 parasites/goat). Once the goat model of
infection was established, the efficacy study could be conducted to
investigate the curative potential of the three lead diamidines.
Complete curative efficacy was seen for the whole five month
follow up period in the positive control group, treated with 5 mg/
kg of diminazene. Additional complete curative efficacy was
Table 3. A five month follow up of an efficacy study for a T. evansi experimentally infected goat model, using a card agglutination
test (CATT/T. evansi), after treatment with Diminazene, DB 75, DB 867 or DB 1192 at various compound doses.
Group
Compound
Treatment
Goat
No. Follow up goat efficacy using a card agglutination test (CATT/T. evansi) post treatment (in days)
27 1 7 14 21 28 35 42 49 56 70 84 98 112 126 140 150
1 Control 2255 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++
7397 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ D
7374 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++
7314 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ D
2 Diminazene 1773 +++ +++ +++ ++ ++ ++ + + + 2222222 2
5 mg/kg 7396 +++ +++ +++ +++ +++ +++ +++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
7388 +++ ++ 22222222222222 2
3 DB 75 7390 + + + + + + + + + + + + + + + + + + + + + ++ + +++++++ +
2.5 mg/kg 7324 +++ +++ +++ +++ +++ +++ ++ + + 2222222 2
5406 + + + + + + + + + + + + + + + + + + + + + ++ + + + + + +++++ +
4 DB 867 7319 +++ ++ ++ 2222222222222 2
2.5 mg/kg 5674 + + + + + + + + + + + ++++++ + 22222 2
7386 + + + + + + + + + + + + + + + + + + + +++++++ +
5 DB 1192 7379 +++ +++ +++ +++ Rem
2.5 mg/kg 7387 +++ +++ +++ +++ Rem
7361 +++ +++ ++ ++ +++ +++ D
6 DB 75 5622 + + + + + + + + ++++++2222222 2
1.25 mg/kg 7366 +++ +++ +++ +++ +++ +++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
7369 +++ +++ +++ +++ +++ +++ +++ ++ + + 222222 2
7 DB 867 7372 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ ++ ++ ++ ++ ++ +++
1.25 mg/kg 7341 + + + + + + + + + ++ + + + + + + ++ + +++++++ + + + +
7339 + + + + + + + + +++++++++++++ + + + +
8 DB 1192 7384 +++ +++ +++ +++ Rem
1.25 mg/kg 7383 +++ +++ +++ +++ Rem
7360 +++ +++ +++ +++ Rem
Results are depicted as strongly positive (+++), intermediate (++), weak (+) or negative (2) for agglutination, when goat plasma was mixed with an antigenic reagent,
along with goats, which died (D) or were removed from the project (Rem) during the study period.
doi:10.1371/journal.pone.0020836.t003
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1.25 mg/kg doses of DB 75. It may even be possible that this
compound could cure T. evansi infected goats at a lower dose than
1.25 mg/kg. With DB 867, curative efficacy was seen in the higher
treatment dose (2.5 mg/kg) while for the lower (1.25 mg/kg) dose
a relapse was seen during the final month of the follow up period.
Since the goats were housed in fly-proof facilities, the potential risk
of re-infection is small, together with the knowledge that the
control goats (which underwent no treatment) were also housed in
a separate fly-proof pen within the research building. On the other
hand, DB 1192 was not effective at either dose tested and the goats
became parasitaemic just one month post treatment.
The pharmacokinetic study was performed to collect informa-
tion for DB 75, DB 867 and DB 1192 within infected goats and to
determine the pharmacokinetic profiles for each compound,
including the standard drug, diminazene. By falling below the
therapeutic threshold level (as did DB 1192), we can clearly
visualise treatment failures due to inadequate compound concen-
trations in the blood. DB 75 and DB 867 appear to accumulate
within the body, as determined through their long half lives. Since
no differences were seen between the high (2.5 mg/kg) and low
(1.25 mg/kg) doses tested, it may be that a point of saturation
within the body was reached. If a higher dose is administered, a
larger amount of compound will be bound to tissue, yet the
amount free in the body may be the same. However, it is difficult
to support such a hypothesis based solely on plasma concentration
data and one would therefore require more in-depth research into
the accumulation and tissue-binding properties of diamidines in
general as well as the investigation of any injection-site residues.
The phenomenon of relapse cases in both human and animal
trypanosomiasis is not fully understood and many factors, such as
drug resistant strains, reinfection or insufficient drug levels at a
given site of the body, can be attributed as possible explanations
for this [18]. Although there are rare reported cases where T. evansi
has established CNS infections [19], the extent to which these
infections contribute to overall disease morbidity and mortality is
unknown. Based on their dicationic nature, diamidines are not
capable of crossing the blood-brain barrier and hence would not
be effective in a CNS infection. If trypanosomes have an ability to
enter compartments (for example, cartilage), which have a reduced
blood flow, then insufficient drug levels may permeate these
compartments, hence ‘‘hidden’’ trypanosomes will not be exposed
Table 4. A five month follow up of an efficacy study for a T. evansi experimentally infected goat model, using the polymerase
chain reaction (PCR), after treatment with Diminazene, DB 75, DB 867 or DB 1192 at various compound doses.
Group
Compound
Treatment
Goat
No. Follow up goat efficacy using polymerase chain reaction (PCR) post treatment (in days)
27 1 7 14 21 28 35 42 49 56 70 84 98 112 126 140 150
1 Control 2255 + ++++++++++++++++
7397 + +++++++++++++D
7374 + ++++++++++++++++
7314 + ++++++++ + + D
2 Diminazene 1773 + 2222222222222222
5 mg/kg 7396 + 2222222222222222
7388 + 2222222222222222
3 DB 75 7390 + 2222222222222222
2.5 mg/kg 7324 + 2222222222222222
5406 + 2222222222222222
4 DB 867 7319 + 2222222222222222
2.5 mg/kg 5674 + 2222222222222222
7386 + 2222222222222222
5 DB 1192 7379 + 2 ++Rem
2.5 mg/kg 7387 + 22+ Rem
7361 + 2222+ D
6 DB 75 5622 + 2222222222222222
1.25 mg/kg 7366 + 2222222222222222
7369 + 2222222222222222
7 DB 867 7372 + 2222222222222+++
1.25 mg/kg 7341 + 2222222222222+++
7339 + 22222222222222++
8 DB 1192 7384 + +++Rem
1.25 mg/kg 7383 + +++Rem
7360 + +++Rem
The results are depicted as negative (2) or positive (+) for the presence of parasite DNA in goat blood samples, along with goats, which died (D) or were removed from
the project (Rem) during the study period.
doi:10.1371/journal.pone.0020836.t004
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the drug within the body has been eliminated completely, these
trypanosomes would reinvade the bloodstream and produce the
high parasitaemia observed in the goats after 4.5 months post
treatment with DB 867 at 1.25 mg/kg.
In conclusion, this efficacy trial into T. evansi infected goats has
enabled three selected lead diamidine compounds to be evaluated,
of which two (DB 75 and DB 867) demonstrated comparable
efficacy to the standard drug (diminazene aceturate). DB 75 was
equally effective at a quarter of the dose used (1.25 mg/kg) and
possibly even at lower doses, than diminazene and DB 867 was
equally effective at half the dose used (2.5 mg/kg). DB 75 and DB
867 warrant further investigation as potential clinical candidates
against T. evansi infection.
Figure 1. Plasma profiles obtained for the standard drug and test compounds used in a T. evansi experimental goat model of
infection. Drug plasma concentrations of a) diminazene at 5 mg/kg (purple), b) DB 1192 at 2.5 mg/kg (orange) and 1.25 mg/kg (green), c) DB 75 at
2.5 mg/kg (orange) and 1.25 mg/kg (green) and d) DB 867 at 2.5 mg/kg (orange) and 1.25 mg/kg (green) are depicted. Horizontal red line shows ten-
times the IC50 for that respective compound.
doi:10.1371/journal.pone.0020836.g001
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